Literature DB >> 27409728

MicroRNA expression profiling of Chinese follicular lymphoma by microarray: A preliminary study.

Yi Pan1, Yan Guo2, Ye Luo3, Hua Li4, Yong Xu5.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) have been widely regarded as crucial regulators in various biological processes involved in carcinogenesis. However, the comprehensive miRNA profiles of Chinese follicular lymphoma (FL) remains completely unknown.
METHODS: The Exiqon miRCURY LNA™ microRNA Array (v.18.0) was used to detect the miRNA expression profiles of three Chinese FL samples, and compared to three reactive lymphatic nodes (RLN). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to confirm the selected miRNAs in different series. Three databases (miRAnda, miRBase and TargetScan) were used to predict the putative target genes. Bioinformatic analysis (gene ontology analysis and pathway analysis) was performed for further evaluation.
RESULTS: The microarray assay demonstrated that 1643 miRNAs were expressed; in which 103 miRNAs were upregulated and 68 miRNAs were downregulated, according to P-value (<0.05) and fold change (FC>2-fold). Furthermore, qRT-PCR was used to confirm that miR-17-5p, miR-20a-5p and miR-19a-3p were upregulated, and miR-3615 was downregulated (P<0.05). Bioinformatic analysis (gene ontology analysis and pathway analysis) was used for further evaluation. Pathway analysis indicated that 25 pathways corresponded to differentially expressed miRNAs (P-value cut-off is 0.05). Furthermore, miR-17-5p, miR-20a-5p and miR-19a-3p were validated by qRT-PCR in an independent series including five FL3a and five RLN cases. Data analysis revealed that the changing trend of miR-19a-3p and miR-17-5p expression in the independent series was basically identical with that of the microarray data.
CONCLUSIONS: Our results are the first to reveal the miRNA expression profiling of Chinese FL and three upregulated miRNAs. Furthermore, the expression of miR-19a-3p and miR-17-5p were found to be significantly upregulated in FL3a. Further study needs to be urgently performed to reveal its potential role in the pathogenesis of FL in the near future.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Follicular lymphoma; Signaling pathway; miRNAs profiling

Mesh:

Substances:

Year:  2016        PMID: 27409728     DOI: 10.1016/j.intimp.2016.07.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Downregulation of miR‑19a‑3p promotes invasion, migration and bone metastasis via activating TGF‑β signaling in prostate cancer.

Authors:  Qingde Wa; Li Li; Hongcheng Lin; Xinsheng Peng; Dong Ren; Yan Huang; Peiheng He; Shuai Huang
Journal:  Oncol Rep       Date:  2017-11-13       Impact factor: 3.906

2.  The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients.

Authors:  Yong Mao; Chengda Zou; Fanyi Meng; Jiehong Kong; Weipeng Wang; Dong Hua
Journal:  Oncotarget       Date:  2017-12-11

3.  Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis.

Authors:  Xing-Ya Guo; Chong-Xin He; Yu-Qin Wang; Chao Sun; Guang-Ming Li; Qing Su; Qin Pan; Jian-Gao Fan
Journal:  Biomed Res Int       Date:  2017-06-21       Impact factor: 3.411

4.  Expression and clinical significance of miR-3615 in hepatocellular carcinoma.

Authors:  Xin Yuan; Yize Zhang; Zujiang Yu
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

5.  An integrated analysis revealed different microRNA-mRNA profiles during skeletal muscle development between Landrace and Lantang pigs.

Authors:  Shuihua Xie; Luxi Chen; Xumeng Zhang; Xiaohong Liu; Yaosheng Chen; Delin Mo
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

Review 6.  The Role of Noncoding RNAs in B-Cell Lymphoma.

Authors:  Jingwen Li; Jing Zou; Xiaoyue Wan; Chunyan Sun; Fei Peng; Zhangbo Chu; Yu Hu
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.